FDA firms up JAK inhibitor warnings after Xeljanz reviewThe FDA has concluded its safety review of Pfizer’s JAK inhibitor Xeljanz and Xeljanz XR, requiring revised warnings Share XFDA firms up JAK inhibitor warnings after Xeljanz reviewhttps://pharmaphorum.com/news/fda-firms-up-jak-inhibitor-warnings-after-xeljanz-review/
AbbVie’s Rinvoq cleared in EU for atopic dermatitisThe FDA may be reluctant to trust JAK inhibitors, but the European Commission is more willing, and has Share XAbbVie’s Rinvoq cleared in EU for atopic dermatitishttps://pharmaphorum.com/news/abbvies-rinvoq-is-first-jak-drug-cleared-in-eu-for-atopic-dermatitis/
FDA holds back from action over Xeljanz safety studyThe FDA has said it will wait for additional results from last week’s trial showing an increased risk Share XFDA holds back from action over Xeljanz safety studyhttps://pharmaphorum.com/news/fda-holds-back-from-action-over-xeljanz-safety-study/
Bad news for Pfizer as blockbuster Xeljanz flunks safety studyJAK inhibitor Xeljanz is one of Pfizer’s top-selling drugs, despite a ‘black box’ warning for blood clots and Share XBad news for Pfizer as blockbuster Xeljanz flunks safety studyhttps://pharmaphorum.com/news/bad-news-for-pfizer-as-blockbuster-xeljanz-flunks-safety-study/
